April 9, 2021
HBW Insight
The Trademark Trial and Appeal Board (TTAB) agreed with Vagisil feminine care product marketer Combe Inc. that Marke Enterprises LLC’s proposed trademark VAGISERT for its vaginal antifungal preparation would cause marketplace confusion and its registration should be rejected. Finnegan attorneys Douglas Rettew, Anna Naydonov, and Sydney English represented Combe and stated that the TTAB decision recognizes the marketplace power of a popular brand like Vagisil as well as Combe’s Vagistat brand. They said:
“This decision shows that the TTAB recognizes the commercial magnetism of brands like Vagisil and Vagistat and the harm that can arise from similar marks, like Vagisert. It also shows that, when one can prove that a brand is legally ‘famous,’ as Combe did here for Vagisil, the TTAB will afford that mark a wide and broad scope of protection. Like all trademark owners, OTC drug manufacturers should federally register their important brands (although that’s not required to assert rights) and should establish and follow a robust enforcement program to challenge and stop similar marks."
Read "50 Years After Pioneering Vaginal Care Branding, Combe Fends Off Similar Competing Trademark"
Press Release
October 6, 2026
Commentary
Federal Circuit Revives Whistleblower Complaint Over VA's AI Claims-Processing Tool
September 25, 2026
Award/Ranking
Finnegan Named an IP Litigation Powerhouse in BTI Litigation Outlook 2027
September 24, 2026
Award/Ranking
Finnegan Receives Top Tier Rankings in World Trademark Review’s Inaugural Copyright 1000 2026
September 23, 2026
Press Release
Finnegan Secures Precedential Pro Bono Federal Circuit Victory for AI Whistleblower
September 23, 2026
Commentary
New Thomas Pink Womenswear Lines Strain ‘Pink’ Pact with Victoria’s Secret
September 21, 2026
Commentary
FORUM IP Talks: Dr. Jochen Herr on UPC, FRAND, and Cross-Border Enforcement Topics
September 20, 2026
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.